



October 9, 2012

For Immediate Release

UMN Pharma Inc.

Memorandum of Understandings for the Co-development and Exclusive Commercialization
Rights of UMN Pharma's Recombinant Influenza HA Vaccine in South Korea
with ILDONG PHARMACEUTICAL

Akita, Japan, October 9, 2012 – UMN Pharma Inc. (“UMN Pharma”; headquarters: Akita, President & CEO: Tatsuyoshi Hirano) announced today that it entered into a memorandum of understandings (“MOU”) for recombinant influenza HA vaccines, UMN-0502, UMN-0501 and UMN-0901 (the “Products”), to co-develop and exclusively commercialize in South Korea with ILDONG PHARMACEUTICAL Co., Ltd. (“ILDONG”; headquarters: Seoul, Chairman & CEO: Jung-chi Lee) on October 4, 2012. A definitive agreement is planned to be concluded in December.

The Products are cell culture based influenza HA vaccine manufactured through BEVS (Baculovirus Expression Vector System), a next generation technology platform for manufacturing of biopharmaceutical products. In Japan, UMN Pharma is co-developing UMN-0502 (a seasonal influenza HA vaccine, under preparation for Phase III clinical trials) and UMN-0501 (H5N1 avian influenza HA vaccine, under Phase II) with Astellas Pharma Inc.

Under the terms of the MOU, UMN Pharma grants to ILDONG co-development and exclusive commercialization rights for the Products in South Korea. ILDONG will bear all the clinical development costs. UMN Pharma will supply the drug substances to ILDONG. ILDONG will be manufacturing final commercial products and will be selling the commercial products.

For more information on, contact:

Business Development Division

Tel: +81-45-624-8341

e-mail: press@umnpharma.com